SRPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the provided data, Sarepta Therapeutics Inc (SRPT) does not present a strong buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators are bearish, the financial performance is weak, and hedge funds are selling significantly. While there are some positive catalysts like analyst price target increases and potential industry tailwinds, the overall sentiment and financial health of the company suggest holding off on investment at this time.
The technical indicators for SRPT are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 27.281, and the moving averages indicate a downward trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 17.333), with resistance levels at R1: 20.74 and R2: 21.793.
Analyst price target increases from Baird, Barclays, and Bernstein, reflecting some optimism about the company's potential.
Industry-wide positive sentiment for biotech stocks in 2026, including expectations of mergers and acquisitions and strong fundamentals.
Weak financial performance in Q3 2025, with significant YoY declines in revenue (-14.52%), net income (-635.38%), and EPS (-629.41%).
Hedge funds are aggressively selling, with a 12693.27% increase in selling activity over the last quarter.
H.C. Wainwright's skepticism about the EMBARK study data, reiterating a Sell rating with a $5 price target.
No recent congress trading data or influential figure activity to support investor confidence.
Sarepta's financial performance in Q3 2025 was poor, with revenue dropping to $399.36M (-14.52% YoY), net income plummeting to -$179.95M (-635.38% YoY), and EPS falling to -1.8 (-629.41% YoY). Gross margin also declined to 62.08 (-22.63% YoY).
Analyst ratings are mixed. Baird raised its price target to $22 and Barclays to $20, both with neutral or equal weight ratings. Wedbush initiated coverage with an Outperform rating and a $32 price target, citing potential upside from Elevidys re-approval. However, H.C. Wainwright reiterated a Sell rating with a $5 price target, expressing skepticism about the EMBARK study data.
